Question Bank › Strong facts, held-back story

Strong facts, held-back story

Strong facts, held-back story: management reports concrete strengthening but deliberately keeps expectations below it

Calls Tested
460
Answered YES
101
Hit Rate
22%
rare by design

Regeneron Pharmaceuticals, Inc. (REGN) — this company's answers

NO on the Q4 2022 call 2023-02-03 C
The model's full reasoning — Q4 2022 call → NO我们根据提供的财报电话会议记录,判断管理层是否同时做到了:(1) 报告了已经发生的、实际的业务强劲表现(如订单、销量、客户、活动、胜利、利用率或产出方面的真实改善,描述为现在正在发生,而非希望发生);以及 (2) 明显抑制了这种强劲表现——故意将陈述的预期、预测或框架保持在比报告事实所支持的更保守的水平。 检查记录内容: - 关于Eylea:Marion提到“Eylea performance in the market... continues to be very strong”,并提到“year growing at 8% to $6.3 billion”,以及“very strong competitive performance”。这是实际发生的强劲表现。 - 关于Dupixent:全球净销售额增长42%(按固定汇率),美国增长44%,并提到“strong growth continuing across atopic dermatitis, asthma, nasal polyps with additional contributions from recent launches”。这是实际强劲。 - 关于Libtayo:全球净销售额增长44%(按固定汇率),美国增长36%,并提到“steady growth in utilization”和“customer ordering has accelerated following the chemotherapy combination approval”。这是实际强劲。 现在看管理层是否抑制了预期。在电话会议中,管理层给出了2023年的财务指引:SG&A 2.13-2.2B,R&D 3.725-3.925B,COCM 720-800M,资本支出825-950M,毛利率90-92%,税率11-13%。这些是标准指引,没有明显上调或下调。但我们需要看是否有迹象表明管理层在强劲结果面前故意保持保守。 在回答关于Eylea竞争的问题时,Marion说“we continue to hear that first nAb use has been modest and results, in some cases, have resulted in patients switching back to other agents, including EYLEA probably most frequently EYLEA.” 这暗示了竞争压力,但并没有抑制预期。 在回答关于COPD的问题时,Len说“we are totally blinded to the evaluation that was done on the interim analysis. We have said we set it at a reasonable bar, but it was only a fraction of the patients. So, you never know how this is going to turn out, we would not be as confident about something like this compared to another classic Type 2 inflammatory disease.” 这表现出谨慎,但这是针对一个尚未公布结果的试验,并非针对已报告的实际强劲表现。 在回答关于成本刺激平台的问题时,Len说“we think we are not going to go too fast where one would be reckless. We have to be careful. But we do think there is an opportunity for an accelerated approval if we follow the new approach the FDA has laid out.” 这表现出谨慎,但这是关于未来监管路径,并非抑制当前强劲表现。 在回答关于MUC16的问题时,George说“we are hoping that increasingly we might be able to move a little bit more quickly through some of these dose escalation stages to get to the active doses with these other agents.” 这表现出希望,但并非抑制。 总体来看,管理层报告了强劲的实际业绩,但在指引和评论中并没有明显表现出故意将预期保持在比事实更低的水平。他们给出了标准指引,没有上调,但也没有明确表示“我们故意保守”。在回答问题时,他们表现出谨慎,但这是针对具体未决事项,而非针对已报告的实际强劲表现。 因此,没有看到明显的“抑制”迹象。管理层没有说“尽管我们业绩强劲,但我们保持保守预期”之类的话。他们只是报告了业绩,并给出了常规指引。 所以,答案应为NO。

← Back to the full REGN analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management BOTH (1) report concrete, already-occurring strength in the business — real improvement in the recent period such as rising orders, volumes, customers, activity, wins, utilization, or output, described as actually happening now rather than hoped for — AND (2) visibly HOLD THE STORY BACK from that strength — deliberately keeping stated expectations, forecasts, or framing more modest than the reported facts would support? Answer YES when both halves come through in management's own words as one coherent posture, in whatever form fits the business. The RESTRAINT half may show up in many ways, and any genuine expression of it counts — for example: management declining to raise, or raising only modestly, its outlook despite results plainly running ahead of it; management explicitly cautioning against extrapolating or annualizing the strong period even while confirming the strength is real; management choosing not to call the improvement a trend yet, saying it wants more quarters of evidence before it will; management emphasizing risks, execution work still ahead, or reasons for prudence at the very moment the underlying numbers are strengthening; management describing demand or momentum stronger than what it has built into its own plan or guidance; or management answering bullish analyst framings by talking the enthusiasm DOWN rather than up. What matters is the direction of the gap: the facts reported are running AHEAD of the story management is willing to tell, and the modesty is management's own deliberate choice — a stance of under-promising — rather than a response to genuine deterioration. Answer NO if the reported period is weak, mixed, or merely stabilizing, so there is no real strength for the story to lag. NO if management is promotional or freely extrapolates the strength — raising expectations in line with or beyond the results — however justified. NO if the caution reflects actual visible deterioration, softening demand, or specific problems management describes, rather than deliberate restraint amid strength. NO if the conservatism is only boilerplate risk language, standard safe-harbor phrasing, or routine 'prudent guidance' wording without a visible gap between reported facts and stated expectations. NO if the restraint is merely management declining to comment on distant years in the ordinary way. NO if the posture appears only in an analyst's characterization (such as calling guidance conservative) that management does not itself substantiate in how it talks about the business. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
CRGO Freightos Limited Q1 2024 2024-05-20 C+
AZEK The AZEK Company Inc. Q2 2024 2024-05-08 B+
GL Globe Life Inc. Q1 2024 2024-04-23 F
PBR Petróleo Brasileiro S.A. - Petrobras Q4 2023 2024-03-08 D
NICE NICE Ltd. Q4 2023 2024-02-22 B+
DXCM DexCom, Inc. Q4 2023 2024-02-08 B+
EGP EastGroup Properties, Inc. Q4 2023 2024-02-08 B
MET MetLife, Inc. Q4 2023 2024-02-01 B+
HP Helmerich & Payne, Inc. Q1 2024 2024-01-30 C
BRBR BellRing Brands, Inc. Q4 2023 2023-11-21 B+
AEP American Electric Power Company, Inc. Q3 2023 2023-11-02 C+
PNNT PennantPark Investment Corporation Q3 2023 2023-08-10 B+
SPT Sprout Social, Inc. Q2 2023 2023-08-04 B+
AFL Aflac Incorporated Q2 2023 2023-08-02 C+
CTO CTO Realty Growth, Inc. Q2 2023 2023-07-28 B
DAL Delta Air Lines, Inc. Q2 2023 2023-07-13 A
GVP GSE Systems, Inc. Q1 2023 2023-05-15 D
SPIR Spire Global, Inc. Q1 2023 2023-05-10 B
THS TreeHouse Foods, Inc. Q1 2023 2023-05-08 B+
SBRA Sabra Health Care REIT, Inc. Q1 2023 2023-05-04 B
BRX Brixmor Property Group Inc. Q1 2023 2023-05-02 A
CALX Calix, Inc. Q1 2023 2023-04-20 C+
DKS DICK'S Sporting Goods, Inc. Q4 2022 2023-03-07 B
VRE Veris Residential, Inc. Q4 2022 2023-02-22 D
ADPT Adaptive Biotechnologies Corporation Q4 2022 2023-02-14 C+
UAL United Airlines Holdings, Inc. Q4 2022 2023-01-18 B
ICL ICL Group Ltd Q3 2022 2022-11-09 B+
MEC Mayville Engineering Company, Inc. Q3 2022 2022-11-05 B+
SYY Sysco Corporation Q1 2023 2022-11-01 C+
TMCI Treace Medical Concepts, Inc. Q2 2022 2022-08-13 B+
EXFY Expensify, Inc. Q2 2022 2022-08-12 D
WD Walker & Dunlop, Inc. Q2 2022 2022-08-09 C+
SGRY Surgery Partners, Inc. Q2 2022 2022-08-02 B+
SYM Symbotic Inc. Q3 2022 2022-08-01 B+
CIVB Civista Bancshares, Inc. Q2 2022 2022-07-31 B
LIN Linde plc Q2 2022 2022-07-28 B+
PRGS Progress Software Corporation Q2 2022 2022-06-28 B+
SQM Sociedad Química y Minera de Chile S.A. Q1 2022 2022-05-19 C+
IRTC iRhythm Technologies, Inc. Q1 2022 2022-05-07 C+
FARM Farmer Bros. Co. Q3 2022 2022-05-07 D
BFIN BankFinancial Corporation Q1 2022 2022-05-06 A
SOPH SOPHiA GENETICS SA Q4 2021 2022-03-15 C
FLUX Flux Power Holdings, Inc. Q2 2022 2022-02-10 D
VVV Valvoline Inc. Q1 2022 2022-02-09 C+
GTES Gates Industrial Corporation plc Q4 2021 2022-02-07 C+
LC LendingClub Corporation Q4 2021 2022-01-26 A
ALHC Alignment Healthcare, Inc. Q3 2021 2021-11-06 B+
WMB The Williams Companies, Inc. Q3 2021 2021-11-02 B
SXC SunCoke Energy, Inc. Q3 2021 2021-11-01 A
MD Pediatrix Medical Group, Inc. Q3 2021 2021-10-28 B
CPRX Catalyst Pharmaceuticals, Inc. Q2 2021 2021-08-10 C+
AMC AMC Entertainment Holdings, Inc. Q2 2021 2021-08-09 D
UFI Unifi, Inc. Q4 2021 2021-08-07 B
CRS Carpenter Technology Corporation Q4 2021 2021-08-01 A
AX Axos Financial, Inc. Q4 2021 2021-07-29 C+
EHTH eHealth, Inc. Q2 2021 2021-07-29 F
JPM JPMorgan Chase & Co. Q2 2021 2021-07-13 A
T AT&T Inc. Q3 2018 2018-10-24 C+
CP Canadian Pacific Railway Limited Q2 2018 2018-07-19 B+
MKC McCormick & Company, Incorporated Q2 2018 2018-06-28 C+
HPE Hewlett Packard Enterprise Company Q2 2018 2018-05-22 B+
FSS Federal Signal Corporation Q1 2018 2018-05-12 A
FOSL Fossil Group, Inc. Q1 2018 2018-05-08 C
BCOV Brightcove Inc. Q1 2018 2018-04-26 B+
ILMN Illumina, Inc. Q1 2018 2018-04-24 A
HLX Helix Energy Solutions Group, Inc. Q1 2018 2018-04-24 B+
ATI Allegheny Technologies Incorporated Q1 2018 2018-04-24 B
PCRX Pacira BioSciences, Inc. Q4 2017 2018-02-28 C
TSLX Sixth Street Specialty Lending, Inc. Q4 2017 2018-02-22 C+
LII Lennox International Inc. Q4 2017 2018-02-06 B+
UNH UnitedHealth Group Incorporated Q4 2017 2018-01-16 A
RACE Ferrari N.V. Q3 2017 2017-11-02 C+
HTLF Heartland Financial USA, Inc. Q3 2017 2017-10-30 B+
HSTM HealthStream, Inc. Q3 2017 2017-10-24 C
PII Polaris Inc. Q3 2017 2017-10-24 C+
BCE BCE Inc. Q2 2017 2017-08-05 B+
BIIB Biogen Inc. Q2 2017 2017-07-25 B
ABM ABM Industries Incorporated Q2 2017 2017-06-08 B
DAN Dana Incorporated Q1 2017 2017-05-02 B
SHOO Steven Madden, Ltd. Q1 2017 2017-04-21 C
PPG PPG Industries, Inc. Q1 2017 2017-04-20 C
AAT American Assets Trust, Inc. Q4 2016 2017-02-15 C+
BDC Belden Inc. Q4 2016 2017-02-02 B
BMO Bank of Montreal Q4 2016 2016-12-06 B
FNV Franco-Nevada Corporation Q3 2016 2016-11-08 B+
WAT Waters Corporation Q3 2016 2016-10-25 C
BOH Bank of Hawaii Corporation Q3 2016 2016-10-24 A
MAT Mattel, Inc. Q3 2016 2016-10-19 C
ARAY Accuray Incorporated Q4 2016 2016-08-17 B
VRNS Varonis Systems, Inc. Q2 2016 2016-08-09 B+
CGNX Cognex Corporation Q2 2016 2016-08-01 A
TRV The Travelers Companies, Inc. Q2 2016 2016-07-21 C+
ESE ESCO Technologies Inc. Q2 2016 2016-05-03 A
INGR Ingredion Incorporated Q1 2016 2016-05-01 B+
SPR Spirit AeroSystems Holdings, Inc. Q1 2016 2016-04-29 D
ACCO ACCO Brands Corporation Q1 2016 2016-04-27 B+
DD DuPont de Nemours, Inc. Q1 2016 2016-04-26 B+
CAL Caleres, Inc. Q4 2015 2016-03-15 C+
HPP Hudson Pacific Properties, Inc. Q4 2015 2016-02-25 C
HD The Home Depot, Inc. Q4 2015 2016-02-23 A
JHX James Hardie Industries plc Q3 2016 2016-02-19 B+

How the model reasoned

GTES · Q4 2021 → YESThe question is: Does management BOTH report concrete, already-occurring strength AND visibly HOLD THE STORY BACK from that strength? YES Management reports concrete, already-occurring strength in the business—rising orders, record backlog, book-to-build above 1, strong January order rates, specific design wins, and demand exceeding supply—while deliberately holding the story back by framing 2022 expectations as measured, pragmatic, and cautious, noting ongoing challenges through Q1 and not fully embedding the current momentum into the guidance range. This posture appears in their own words as they describe the facts running ahead of the outlook they are willing to share. The restraint is not mere boilerplate but a visible choice to under-promise relative to the reported strength.
BCOV · Q1 2018 → YESThe question is: Does management BOTH report concrete, already-occurring strength AND visibly HOLD THE STORY BACK from that strength? YES Management reports concrete strength in Q1 2018: revenue $41.2M exceeded high end of guidance, adjusted EBITDA positive $900k well above high end, recurring dollar retention 103% (multi-year high), strong bookings across businesses/geographies, notable wins including large auto company deal, Europe best 3+ years, completed commodity pricing reset, and digital marketing/enterprise activity showing productivity gains. They visibly hold the story back: full-year revenue guidance $165-168M (roughly flat vs. Q1 run-rate implying ~$164.8M), Q2 revenue guidance $41.
PII · Q3 2017 → YESThe question is: Does management BOTH report concrete, already-occurring strength AND hold the story back from that strength? YES The transcript shows clear evidence of both elements in management's posture. They report concrete, already-occurring strength in the recent period—Q3 sales up 25% (adjusted), North American retail up 13% with RZR and NDN ahead, September as Polaris' highest retail month ever, August among top three 2017 months, off-road vehicles and Polaris retail up versus 2015 (not an easy comp), dealer inventory down 7%, and strong international/PG&A growth—while explicitly raising 2017 guidance (sales 18-19%, ORV/Snow mid-single digits, EPS $4.

More from the question bank

Ready-to-run scale already paid for and now Fresh change already executed, benefit mostlPersonal bests piling upOrder-of-magnitude gapQuietly replacing the old wayUpside surprise with durable, still-buildingAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.